Nasseri provides close, ongoing monitoring to ensure your treatment is both safe and effective
More specifically speaking, GLP-1 receptor activation facilitates the presynaptic release of GABA into RGCs via the Gs/cAMP/PKA/Phospholipase C (PLC)/IP3/Ca2+/CaM signaling pathway, ultimately increasing the GABAergic miniature inhibitory postsynaptic currents (m-IPSCs) frequency and contrast sensitivity (Shao et al., 2024)

The most frequently reported adverse events (AEs) of GLP-1 RAs were gastrointestinal adverse drug reactions, including nausea, vomiting, and abdominal pain, which were closely related to activation of central and peripheral GLP-1 receptors ( In a recent network meta-analysis, overall GLP-1 RAs significantly increased the incidence of gastrointestinal AEs compared with placebo or conventional treatment, and the odds ratios for nausea, vomiting and diarrhea from GLP-1 RAs were 11.8 (95% CI, 2.8946.9), 51.7 (95% CI, 7.07415), and 4.93 (95% CI, 1.7514.7), respectively ( Methods Data sources This retrospective pharmacovigilance study was conducted based on the FDA Adverse Event Reporting System (FAERS) database
doi: 10.3390/medsci6020032 52 HeL
If you are deficient in these, your body cannot use its antioxidants effectively